The Importance of Adjuvant Agents in Acute Intrathecal Baclofen Withdrawal: Case Report and Review of the Literature

Christopher M. Wang, Susan E. Opper

Department of Anesthesiology, University of Missouri – Kansas City School of Medicine, Kansas City, Missouri, USA..

DOI: 10.4236/ojanes.2012.24024                

Abstract

Objective: Baclofen (β-p-chlorophenyl-GABA) selectively activates the GABA_B subtype of γ-aminobutyric acid (GABA) receptors, a group of receptors known to provide inhibitory neurotransmission in the central nervous system. Available for over thirty years in oral form for the treatment of skeletal muscle spasticity, its availability now includes continuous intrathecal infusion via an internally implanted pump. While ideal for long-term attenuation of symptoms, this treatment modality can also become disastrous should the pump empty and withdrawal subsequently ensue. Case Report: A 48-year-old male with a past medical history of T8 spinal cord injury from a motor vehicle crash originally presented with altered mental status. Because of resultant paraplegia and spasticity from his injuries, a neurosurgeon implanted an intrathecal baclofen pump three years prior to presentation with symptomatic relief. Further exploration revealed that he had missed his scheduled pump refill appointment and interrogation of his pump confirmed a completely empty reservoir. The patient endured a protracted hospital course that included rhabdomyolysis, acute renal failure, lactic acidosis, respiratory failure, and systemic inflammatory response syndrome. Treatment included benzodiazepines, dantrolene, aggressive hydration, opiates, and refill of his intrathecal baclofen pump. His mentation and ventilatory status improved with recovery from his critical illness and eventual discharge. Conclusions: Treatment of intrathecal baclofen withdrawal should focus on restoration of previous intrathecal baclofen levels by refill of the intrathecal pump. Adjuvant medications such as benzodiazepines, propofol, cyproheptadine, dantrolene, tizanidine, and opiates may prove crucial in helping with muscle spasticity while these levels are reestablished. A high index of suspicion, leading to timely initiation of proper treatment, may serve as the most important factor in successful recovery from this life-threatening syndrome.

Keywords

Baclofen; GABA; GABA_B; Intrathecal; Implantable; Infusion Pump; Chronic Pain; Pain Management; Spasticity; Spinal Cord Injury; Neurosurgery; Withdrawal; Analgesia

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	G. M. L. Reis and I. D. G. Duarte, “Baclofen, an Agonist at Peripheral GABAB Receptors, Induces Antinociception via Activation of TEA-Sensitive Potassium Channels,” British Journal of Clinical Pharmacology, Vol. 149, No. 6, 2006, pp. 733-739. doi:10.1038/sj.bjp.0706898
[2]	N. G. Bowery, A. L. Hudson and G. W. Price, “GABAA and GABAB Receptor Site Distribution in the Rat Central Nervous System,” Neuroscience, Vol. 20, No. 2, 1987, pp. 365-383. doi:10.1016/0306-4522(87)90098-4
[3]	D. C. M. Chu, R. L. Albin, A. B. Young and J. B. Penney, “Distribution and Kinetics of GABAB Binding Sites in Rat Central Nervous System: A Quantitative Autoradiographic Study,” Neuroscience, Vol. 34, No. 2, 1990, pp. 341-357. doi:10.1016/0306-4522(90)90144-S
[4]	M. Chebib and G. A. R. Johnston, “GABA-Activated Ligand Gated Ion Channels: Medicinal Chemistry and Molecular Biology,” Journal of Medicinal Chemistry, Vol. 43, No. 8, 2000, pp. 1427-1447. doi:10.1021/jm9904349
[5]	N. G. Bowery, “GABAB Receptor: A Site of Therapeutic Benefit,” Current Opinion in Pharmacology, Vol. 6, No. 1, 2006, pp. 37-43. doi:10.1016/j.coph.2005.10.002
[6]	A. R. Calver, A. D. Medhurst, M. J. Robbins, K. J. Charles, M. L. Evans, D. C. Harrison, M. Stammers, S. A. Hughes, G. Hervieu, A. Couve, S. J. Moss, D. N. Middlemiss and M. N. Pangalos, “The Expression of GABAB1 and GABAB2 Receptor Subunits in the CNS Differs from that in Peripheral Tissues,” Neuroscience, Vol. 100, No. 1, 2000, pp. 155-170. doi:10.1016/S0306-4522(00)00262-1
[7]	M. Slonimski, S. E. Abram and R. E. Zuniga, “Intrathecal Baclofen in Pain Management,” Regional Anesthesia and Pain Medicine, Vol. 29, No. 3, 2004, pp. 269-276. doi:10.1016/j.rapm.2004.01.005
[8]	J. C. Hsieh and R. D. Penn, “Intrathecal Baclofen in the Treatment of Adult Spasticity,” Neurosurgical Focus, Vol. 21, No. 2, 2006, pp. 1-6. doi:10.3171/foc.2006.21.2.6
[9]	P. K. Rawlins, “Intrathecal Baclofen Therapy over 10 Years,” Journal of Neuroscience Nursing, Vol. 36, No. 6, 2004, pp. 322-327. doi:10.1097/01376517-200412000-00005
[10]	N. G. Bowery, B. Bettler, W. Froestl, J. P. Gallagher, F. Marshall, M. Raiteri, T. I. Bonner and S. J. Enna, “International Union of Pharmacology. XXXIII. Mammalian γ-Aminobutyric AcidB Receptors: Structure and Function,” Pharmacological Reviews, Vol. 54, No. 2, 2002, pp. 247-264. doi:10.1124/pr.54.2.247
[11]	R. C. Riley, J. A. Trafton, S. I. Chi and A. I. Basbaum, “Presynaptic Regulation of Spinal Cord Tachykinin Signaling via GABAB But Not GABAA Receptor Activation,” Neuroscience, Vol. 103, No. 3, 2001, pp. 725-737. doi:10.1016/S0306-4522(00)00571-6
[12]	M. Iyadomi, I. Iyadomi, E. Kumamoto, K. Tomokuni and M. Yoshimura, “Presynaptic Inhibition by Baclofen of Miniature EPSCs and IPSCs in Substantia Gelatinosa Neurons of the Adult Rat Spinal Dorsal Horn,” Pain, Vol. 85, No. 3, 2000, pp. 385-393. doi:10.1016/S0304-3959(99)00285-7
[13]	R. Hering-Hanit, “Baclofen for Prevention of Migraine,” Cephalalgia, Vol. 19, No. 6, 1999, pp. 589-591. doi:10.1046/j.1468-2982.1999.019006589.x
[14]	P. Fadda, M. Scherma, A. Fresu, M. Collu and W. Fratta, “Baclofen Antagonizes Nicotine-, Cocaine-, and Morphine-Induced Dopamine Release in the Nucleus Accumbens of Rat,” Synapse, Vol. 50, No. 1, 2003, pp. 1-6. doi:10.1002/syn.10238
[15]	M. Sabetkasai, R. Doost-Mohammady and M. R. Zarrindast, “Opposite Influences of Different Adrenoceptors on Baclofen-Induced Antinociception in Mice,” Pharmacology & Toxicology, Vol. 80, No. 1, 1997, pp. 6-10. doi:10.1111/j.1600-0773.1997.tb00276.x
[16]	R. Olmedo and R. S. Hoffman, “Withdrawal Syndromes,” Emergency Medicine Clinics of North America, Vol. 18, No. 2, 2000, pp. 273-288. doi:10.1016/S0733-8627(05)70124-3
[17]	J. Santiago-Palma, E. D. Hord, R. Vallejo, J. Trella and S. U. Ahmed, “Respiratory Distress after Intrathecal Baclofen Withdrawal,” Anesthesia & Analgesia, Vol. 99, No. 1, 2004, pp. 227-229. doi:10.1213/01.ANE.0000121347.11127.99
[18]	L. B. Green and V. S. Nelson, “Death after Acute Withdrawal of Intrathecal Baclofen: Case Report and Literature Review,” Archives of Physical Medicine and Rehabilitation, Vol. 80, No. 12, 1999, pp. 1600-1604. doi:10.1016/S0003-9993(99)90337-4
[19]	L. W. Kao, Y. Amin, M. A. Kirk and M. S. Turner, “Intrathecal Baclofen Withdrawal Mimicking Sepsis,” The Journal of Emergency Medicine, Vol. 24, No. 4, 2003, pp. 423-427. doi:10.1016/S0736-4679(03)00039-8
[20]	J. C. Ross, A. M. Cook, G. L. Stewart and B. G. Fahy, “Acute Intrathecal Baclofen Withdrawal: A Brief Review of Treatment Options,” Neurocritical Care, Vol. 14, No. 1, 2011, pp. 103-108. doi:10.1007/s12028-010-9422-6
[21]	R. J. Coffey, T. S. Edgar, G. E. Francisco, V. Graziani, J. M. Meythaler, P. M. Ridgely, S. A. Sadiq and M. S. Turner, “Abrupt Withdrawal from Intrathecal Baclofen: Recognition and Management of a Potentially Life-Threatening Syndrome,” Archives of Physical Medicine and Rehabilitation, Vol. 83, No. 6, 2002, pp. 735-741. doi:10.1053/apmr.2002.32820
[22]	C. R. Hansen, J. L. Gooch and T. Such-Neibar, “Prolonged, Severe Intrathecal Baclofen Withdrawal Syndrome: A Case Report,” Archives of Physical Medicine and Rehabilitation, Vol. 88, No. 11, 2007, pp. 1468-1471. doi:10.1016/j.apmr.2007.07.021
[23]	K. A. Leite-Morris, E. Y. Fukudome, M. H. Shoeb and G. B. Kaplan, “GABAB Receptor Activation in the Ventral Tegmental Area Inhibits the Acquisition and Expression of Opiate-Induced Motor Sensitization,” Journal of Pharmacology and Experimental Therapeutics, Vol. 308, No. 2, 2004, pp. 667-678. doi:10.1124/jpet.103.058412
[24]	B. L. Amann, O. Pogarell, R. Mergl, G. Juckel, H. Grunze, C. Mulert and U. Hegerl, “EEG Abnormalities Associated with Antipsychotics: A Comparison of Quetiapine, Olanzipine, Haloperidol and Healthy Subjects,” Human Psychopharmacology: Clinical and Experimental, Vol. 18, No. 8, 2003, pp. 641-646. doi:10.1002/hup.537
[25]	F. Centorrino, B. H. Price, M. Tuttle, W. Bahk, J. Hennen, M. J. Albert and R. J. Baldessarini, “EEG Abnormalities during Treatment with Typical and Atypical Antipsychotics,” The American Journal of Psychiatry, Vol. 159, No. 1, 2002, pp. 109-115. doi:10.1176/appi.ajp.159.1.109